RESUMO
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) has aroused concerns over their increased infectivity and transmissibility, as well as decreased sensitivity to SARS-CoV-2-neutralizing antibodies (NAbs) and the current coronavirus disease 2019 (COVID-19) vaccines. Such exigencies call for the development of pan-sarbecovirus vaccines or inhibitors to combat the circulating SARS-CoV-2 NAb-escape variants and other sarbecoviruses. In this study, we isolated a broadly NAb against sarbecoviruses named GW01 from a donor who recovered from COVID-19. Cryo-EM structure and competition assay revealed that GW01 targets a highly conserved epitope in a wide spectrum of different sarbecoviruses. However, we found that GW01, the well-known sarbecovirus NAb S309, and the potent SARS-CoV-2 NAbs CC12.1 and REGN10989 only neutralize about 90% of the 56 tested currently circulating variants of SARS-CoV-2 including Omicron. Therefore, to improve efficacy, we engineered an IgG-like bispecific antibody GW01-REGN10989 (G9) consisting of single-chain antibody fragments (scFv) of GW01 and REGN10989. We found that G9 could neutralize 100% of NAb-escape mutants (23 out of 23), including Omicron variant, with a geometric mean (GM) 50% inhibitory concentration of 8.8 ng/mL. G9 showed prophylactic and therapeutic effects against SARS-CoV-2 infection of both the lung and brain in hACE2-transgenic mice. Site-directed mutagenesis analyses revealed that GW01 and REGN10989 bind to the receptor-binding domain in different epitopes and from different directions. Since G9 targets the epitopes for both GW01 and REGN10989, it was effective against variants with resistance to GW01 or REGN10989 alone and other NAb-escape variants. Therefore, this novel bispecific antibody, G9, is a strong candidate for the treatment and prevention of infection by SARS-CoV-2, NAb-escape variants, and other sarbecoviruses that may cause future emerging or re-emerging coronavirus diseases.
RESUMO
Arabinogalactan proteins (AGPs) are hyperglycosylated members of the hydroxyproline-rich glycoprotein (HRGP) superfamily and are widely distributed throughout the plant kingdom. In Oryza sativa (rice), the gene expression and biological function of AGPs only have received minimal research attention. Here, we used qRT-PCR to detect the expression patterns of OsAGP genes in various organs, and found that six genes were preferentially expressed in panicles, three genes were specifically expressed in anthers, and one gene in the stigma. Furthermore, using four specific monoclonal antibodies (JIM8, JIM13, LM2, MAC207), we observed the distribution of AGPs in rice anthers, ovules, and embryos. In anthers, the strong fluorescence signals of AGPs were present in tapetum cells, pollen mother cells, and mature pollens, suggesting that AGPs might be related to the development of anther and pollen. In ovules, signals of AGPs were specifically distributed in the three micropylar megaspores of the tetrad, and with intense signals in the egg cell and synergid cells in the mature embryo sac. This suggests that AGPs may be involved in megaspore determination and double fertilization. In embryos, the immunological signals of AGPs appeared in peripheral and inner cells at the early stage, and in the scutellum, plumule, and radicle at the late stage, indicating that AGPs may be associated with organ differentiation and maturation of embryos. In this study, we revealed that AGPs were widely distributed in rice anthers, ovules, and embryos, which lays a foundation for the functional investigation of AGPs in various processes of sexual reproduction.